There is no European strategy to address in the short-time period the regulatory obstacles for using cannabis for medicinal needs, the Council presidency in the EU and the European Fee have confirmed to EURACTIV.  As the clinical community is used to working with particular benchmarks. They have to have arduous studies along with a classificati